Income Statement Perspective Therapeutics, Inc.
Stocks
CATX
US46489V3024
Biotechnology & Medical Research
|
Market Closed -
NYSE
01:30:00 05/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 3.130 USD | +0.32% |
|
-0.95% | +13.82% |
| 19/08 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 14/08 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
| Fiscal Period: December | 2016 (USD) | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 1.01Cr | 71.04L | 14.34L | 14.54L | 9L | |||||
Total Revenues | 1.01Cr | 71.04L | 14.34L | 14.54L | 9L | |||||
Cost of Goods Sold, Total | 49.32L | 54.7L | - | 3.94Cr | 8.42Cr | |||||
Gross Profit | 51.21L | 16.34L | 14.34L | -3.8Cr | -8.33Cr | |||||
Selling General & Admin Expenses, Total | 71.31L | 1.42Cr | 2.11Cr | 2.66Cr | 3.02Cr | |||||
R&D Expenses | 14.27L | 26.02L | 2.13Cr | 22.09L | - | |||||
Other Operating Expenses | - | - | - | - | - | |||||
Other Operating Expenses, Total | 85.58L | 1.68Cr | 4.24Cr | 2.88Cr | 3.02Cr | |||||
Operating Income | -34.37L | -1.52Cr | -4.09Cr | -6.68Cr | -11Cr | |||||
Interest Expense, Total | - | - | -84T | -48T | -4L | |||||
Interest And Investment Income | 59T | 11.22L | 9L | 1.05Cr | 81.14L | |||||
Net Interest Expenses | 59T | 11.22L | 8L | 1.05Cr | 77.38L | |||||
Income (Loss) On Equity Invest. | - | - | -17T | -8T | -2T | |||||
Other Non Operating Income (Expenses) | - | - | 2T | - | 14L | |||||
EBT, Excl. Unusual Items | -33.78L | -1.41Cr | -4.01Cr | -5.63Cr | -10Cr | |||||
Restructuring Charges | - | - | - | - | - | |||||
Impairment of Goodwill | - | - | - | -2.41Cr | - | |||||
Gain (Loss) On Sale Of Assets | -9T | -6L | - | -27T | - | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | -33.87L | -1.47Cr | -4.01Cr | -8.04Cr | -10Cr | |||||
Income Tax Expense | - | - | -26.51L | -20.97L | -8L | |||||
Earnings From Continuing Operations | -33.87L | -1.47Cr | -3.75Cr | -7.83Cr | -10Cr | |||||
Earnings Of Discontinued Operations | - | - | -90.53L | -9L | 5L | |||||
Net Income to Company | -33.87L | -1.47Cr | -4.65Cr | -7.93Cr | -10Cr | |||||
Net Income - (IS) | -33.87L | -1.47Cr | -4.65Cr | -7.93Cr | -10Cr | |||||
Preferred Dividend and Other Adjustments | 3T | - | - | - | - | |||||
Net Income to Common Incl Extra Items | -33.9L | -1.47Cr | -4.65Cr | -7.93Cr | -10Cr | |||||
Net Income to Common Excl. Extra Items | -33.9L | -1.47Cr | -3.75Cr | -7.83Cr | -10Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.33 | -1.03 | -1.74 | -1.23 | -1.4 | |||||
Basic EPS - Continuing Operations | -0.33 | -1.03 | -1.4 | -1.22 | -1.4 | |||||
Basic Weighted Average Shares Outstanding | 1.04Cr | 1.42Cr | 2.68Cr | 6.44Cr | 7.38Cr | |||||
Net EPS - Diluted | -0.33 | -1.03 | -1.74 | -1.23 | -1.4 | |||||
Diluted EPS - Continuing Operations | -0.33 | -1.03 | -1.4 | -1.22 | -1.4 | |||||
Diluted Weighted Average Shares Outstanding | 1.04Cr | 1.42Cr | 2.68Cr | 6.44Cr | 7.38Cr | |||||
Normalized Basic EPS | -0.2 | -0.62 | -0.94 | -0.55 | -0.88 | |||||
Normalized Diluted EPS | -0.2 | -0.62 | -0.94 | -0.55 | -0.88 | |||||
Payout Ratio | -0.27 | - | - | - | - | |||||
Supplemental Items | ||||||||||
EBITDA | -32.27L | -1.48Cr | -4Cr | -6.45Cr | -11Cr | |||||
EBITA | -33.76L | -1.51Cr | -4.09Cr | -6.68Cr | -11Cr | |||||
EBIT | -34.37L | -1.52Cr | -4.09Cr | -6.68Cr | -11Cr | |||||
EBITDAR | -29.23L | -72.58L | -3.99Cr | -6.37Cr | -11Cr | |||||
Effective Tax Rate - (Ratio) | - | - | 6.61 | 2.61 | 0.76 | |||||
Deferred Domestic Taxes | - | - | -26.51L | -20.97L | -8L | |||||
Total Deferred Taxes | - | - | -26.51L | -20.97L | -8L | |||||
Normalized Net Income | -21.11L | -87.88L | -2.51Cr | -3.52Cr | -6.53Cr | |||||
Interest on Long-Term Debt | - | - | 84T | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 84T | 1L | - | - | - | |||||
Selling and Marketing Expenses | 24.4L | 32.28L | - | - | - | |||||
General and Administrative Expenses | 45.82L | 1.09Cr | 2.1Cr | 2.58Cr | 2.91Cr | |||||
Research And Development Expense From Footnotes | 14.27L | 26.02L | 2.13Cr | 4.16Cr | 8.42Cr | |||||
Net Rental Expense, Total | 3L | 2L | 97T | 8L | 11L | |||||
Imputed Operating Lease Interest Expense | - | - | - | 92.9T | 9L | |||||
Imputed Operating Lease Depreciation | - | - | - | 7L | 2L | |||||
Stock-Based Comp., COGS (Total) | 30T | 28T | - | - | 39.45L | |||||
Stock-Based Comp., R&D Exp. (Total) | 1L | 3L | 10L | 22.09L | - | |||||
Stock-Based Comp., S&M Exp. (Total) | 49T | 94T | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | 2L | 9L | 21.75L | 30.12L | 50.21L | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 4L | 13.44L | 31.43L | 52.21L | 89.66L |
- Stock Market
- Stocks
- CATX Stock
- Financials Perspective Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















